Meditoxin® Treatment in Patients With Cervical Dystonia

A Prospective, Randomized, Multi-center, Phase III, Double-blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of MEDITOXIN in Treatment of Cervical Dystonia

To determine the efficacy and safety of Meditoxin in subjects with cervical dystonia compared with placebo (normal saline)

Inclusion Criteria:

• Male or female aged 20 to less than 75 years
• Subjects requiring treatment for a clinical diagnosis of cervical dystonia with Toronto Western Spasmodic Torticollis Rating Scale(TWSTRS)-Total Score >=20 and TWSTRS-Severity score >=10

Exclusion Criteria:

• Subjects with pure anterocollis
• Subjects with neuromuscular junctional disorders (e.g., myasthenia gravis, Lambert-Eaton syndrome)
• A history of an anaphylactic response to Botulinum toxin type A and other involved ingredients of Investigational product
• Subjects of reproductive age who do not agree to use suitable contraceptive methods for the duration of the study